Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer
A recent paper published in The Oncologist has shown that [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer
Results from the NeoAvAx clinical trial were presented at the [...]
Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer
KCSN are formal consultants to NICE and part of the [...]
Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib
In this video interview from Practice Update, Dr Eric Jonasch [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
